What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Group 2352.png

ACEi: angiotensin-converting enzyme inhibitor; CI: confidence interval; CV: cardiovascular; HF: heart failure; HFrEF: heart failure with reduced ejection fraction; HR: hazard ratio; LVEF: left ventricular ejection fraction; OR: odds ratio; KCCQ:Kansas City Cardiomyopathy Questionnaire 
* Stronger Heart: In PROVE-HF, LVEF increased vs baseline from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In PARADIGM-HF, as compared with an Enalapril, ENTRESTO® reduced the risk of hospitalization for heart failure by 21% (HR, 0.79; 95% CI, 0.71 to 0.89; P<0.001) and change in KCCQ clinical summary score at 8 months (between-group difference, 1.64 points; 95% CI, 0.63 to 2.65; P=0.001).2
† ENTRESTO® must not be administered until 36 hours after discontinuing ACEi therapy.3
‡ HR for HF hospitalization 0.79; 95% CI, 0.71 to 0.89; P<0.0012
§ HR for CV death 0.80; 95% CI, 0.71 to 0.89; P<0.0012
# ENTRESTO® was significantly associated with a 5-point or greater improvement in change score difference in combined physical and social activity mean score with adjustment for baseline score at 8-month follow-up (OR, 1.12; 95% CI, 1.00-1.24; P = .04).4

Entresto®: A Brief Clinical Overview

Entresto In Action Video VIDEO

Entresto® in Action: 

 

Acts on 2 critical pathways that contribute to HFrEF5 to inhibit harmful RAAS and enhances the NP system, the in-built protective mechanism of the heart6. 

Group 2375.png
Frame 427318860.png
Efficacy
Frame 427318860-1.png
Safety
Frame 427318860-2.png
Special population
Frame 427318859.png
Meet our patients
Frame 4273188602.png
Dosing

HFrEF= heart failure with reduced ejection fraction 

Entresto® API

PDF
View

References

  1. Januzzi JL, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, Camacho A, Piña IL, Rocha RA, Shah AM, Williamson KM. Association of change in N-terminal pro–B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. Jama. 2019 Sep 17;322(11):1085-95. 

  2. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine. 2014 Sep 11;371(11):993-1004.

  3. Egyptian Drug Authority (EDA). Entresto Approved Leaflet. Approval Date: 07/06/2021.

  4. Chandra A, Lewis EF, Claggett BL, Desai AS, Packer M, Zile MR, Swedberg K, Rouleau JL, Shi VC, Lefkowitz MP, Katova T. Effects of sacubitril/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA cardiology. 2018 Jun 1;3(6):498-505.

  5. Summary Of Product Characteristics (SMPC). Entresto. Available at: https://www.ema.europa.eu/en/documents/product-information/entresto-epar-product-information_en.pdf. Last accessed at: 16/06/2025.

  6. Erdogan BR, Yesilyurt-Dirican ZE, Karaomerlioglu I, Muderrisoglu AE, Sevim K, Michel MC, Arioglu-Inan E. Sacubitril/Valsartan Combination Partially Improves Cardiac Systolic, but Not Diastolic, Function through β-AR Responsiveness in a Rat Model of Type 2 Diabetes. International Journal of Molecular Sciences. 2024 Oct 2;25(19):10617.

Approved by Egyptian Drug Authority: HF0068OA4787/102025. Invalidation date: 04/05/2027. Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg

Entresto QR Code.png

HF0068OA4787/102025 04/05/2027